Streetbeat News

Price Targets

PHVS

JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Pharvaris (NASDAQ:PHVS) and increased the price target from $40 to $49.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:42 pm

SGML

BMO Capital analyst Joel Jackson has maintained an Outperform rating on Sigma Lithium (NASDAQ:SGML) but has reduced the price target from $40 to $38.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:39 pm

PTC

BMO Capital analyst Daniel Jester has maintained an Outperform rating on PTC (NASDAQ:PTC) and increased the price target from $184 to $195.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:37 pm

ADM

Goldman Sachs analyst Adam Samuelson has maintained a Neutral rating on Archer-Daniels Midland (NYSE:ADM) but has reduced the price target from $90 to $67.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:32 pm

NOW

Barclays analyst Raimo Lenschow has maintained an Overweight rating on ServiceNow (NYSE:NOW) and increased the price target from $765 to $870, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:23 pm

REGN

Barclays analyst Carter Gould has maintained an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $935 to $1020.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:21 pm

NBIX

Barclays analyst Carter Gould has maintained an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $145 to $150. This adjustment reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:20 pm

MRK

Barclays analyst Carter Gould has maintained an Overweight rating on Merck & Co (NYSE:MRK) and increased the price target from $130 to $135, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:18 pm

ALLY

BMO Capital analyst James Fotheringham has maintained a 'Market Perform' rating on Ally Financial (NYSE:ALLY) and increased the price target from $36 to $37.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:17 pm

GILD

Barclays analyst Carter Gould has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and increased the price target from $82 to $85.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:17 pm